Summary
Panel Moderator, “Pharma's New Interest in Collaborating Early"
Speakers
- /en/people/d/denn-christopher
Christopher J. Denn
Partner
Related Content
- Big Molecule WatchOctober 18, 2024
Teva’s Denosumab Biosimilar Candidate is Accepted for Review by FDA and EMA
- Big Molecule WatchOctober 16, 2024
Teva and mAbxience Add Additional Oncology Biosimilar Candidate, Expanding Strategic Partnership
- Big Molecule WatchOctober 14, 2024
Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab
- Life Sciences PerspectivesOctober 9, 2024
Running for Rare for NORD
- AlertOctober 8, 2024
Florida District Court Concludes FCA’s Qui Tam Provision Is Unconstitutional
- Big Molecule WatchOctober 7, 2024
PTAB Institutes Eight More IPRs Filed by Merck on Johns Hopkins Pembrolizumab Patents
- Big Molecule WatchOctober 5, 2024
Fresenius and Formycon Receive EC and FDA Approval of Ustekinumab Biosimilar
- Big Molecule WatchOctober 4, 2024
Aflibercept Biosimilar Updates in Europe
- Press ReleaseOctober 22, 2024
Joshua Zachariah Named a Law360 MVP in Mergers & Acquisitions
- Press ReleaseOctober 17, 2024
Goodwin Once Again Number One for M&A
- Awards and RankingsOctober 17, 2024
Goodwin UK Highly Ranked in Chambers UK 2025
- Press Release16 October 2024
Vicebio Announces $100 Million Series B Financing
- Press ReleaseOctober 16, 2024
Goodwin Advises Upstream Bio on $293 Million Upsized Initial Public Offering
- Press ReleaseOctober 10, 2024
Purespring Therapeutics Raises £80 Million
- Press ReleaseOctober 10, 2024
Goodwin Advises insitro on Strategic Agreements with Lilly to Advance Novel Treatments for Metabolic Diseases
- Press ReleaseOctober 7, 2024
Virios Therapeutics and Wex Pharmaceuticals Agree to Business Combination to Form Dogwood Therapeutics